Healthcare in Health Solutions

What are US hospitals doing to improve the health of their communities?

Tree

Twenty years; that’s how much longer someone who spends their life in an affluent neighbourhood might live compared to someone who grows up in a socioeconomically deprived section of the same city. That appears to be the case in major cities across Europe and the United States. This inequality in health outcomes is only to a small part explained by the lack of access to medical care. Last month we published our report, Breaking the dependency cycle which examined the more intransigent causes including access to and opportunities in education, employment, housing, public transport and welfare services . Our report identifies a host of case studies and urges governments and providers to break down organisational barriers and collectively address these wider social determinants of health. Throughout our research, we were able to exchange ideas with our colleagues from the US Center for Health Solutions who last week launched their report Addressing social determinants of health in hospitals that analyses, how US hospitals, in their crucial position within the care system, are investing in social needs. This week’s blog is written by our US colleague, Josh Lee, who leads the firm’s US Healthcare Provider Strategy Practice and first appeared as part of the US Center for Health Solution blog. The article highlights the motivation for the report, identifies challenges and points to key strategies that could be adopted by hospitals and integrated local health systems globally to improve health outcomes.

Continue reading

Posted on 28/07/2017 | 0 Comments

Pharma and the connected patient: How digital technology is enabling patient centricity

Patient-centricity

This week we launched our report Pharma and the connected patient: How digital technology is enabling patient centricity. Our report focusses on pharma’s efforts to utilise smartphone apps, wearables and other digital technologies in an effort to put patients at the centre of new business and operating models. This transformation, from a provider-driven marketplace to a patient-centric health ecosystem, is being driven by the need to demonstrate value to payers and patients and respond to a variety of powerful forces that are transforming healthcare. These forces are requiring pharma to become more agile and to do more for patients than deliver safe and effective drugs.

Continue reading

Posted on 21/07/2017 | 0 Comments

The NHS at 69 – a time to pause, reflect and celebrate

Deloitte-uk-torch

Last week marked the 69th birthday of the NHS and, as is the case with most anniversaries, it provided a reason to reflect on what has been achieved and to contemplate what the future might bring. Today however, the positivity we saw five years ago, when the NHS was lauded at the London Olympic Games, has been replaced with a rising number of concerns over its funding and sustainability. I thought I would use this week’s blog to highlight some of the more positive milestones seen over the past 69 years and contemplate what we can do to ensure that the NHS can celebrate its seventieth birthday in robust health.

Continue reading

Posted on 14/07/2017 | 0 Comments

The smartphone at 10 years old! In what ways is it impacting healthcare?

Smartphone

Last week the smartphone turned ten. This device has revolutionised the way we interact with each other and more importantly with our own health. This week’s blog by Amen Sanghera, an analyst here at the Centre, takes a deeper dive into the key innovations that have enabled consumers to be more active participants in their own health and some of the challenges that still face the use of smartphone technologies in healthcare.

Continue reading

Posted on 07/07/2017 | 0 Comments

Pharma and emerging markets: Unlocking the potential of emerging economies

Plants

Just a few years ago, slowing growth in the US and European pharmaceutical markets led many multinational pharmaceutical companies to seek new forms of growth in emerging markets. The primary growth drivers in emerging markets included increased government commitment to improving healthcare access, growing consumer income and wealth, and a growing prevalence of lifestyle diseases such as cancer and diabetes. However, in just a few short years it seems as though the industry sentiment towards emerging markets has somewhat shifted. This week’s blog, by Matthew Thaxter, an analyst here at the Centre looks some of the reasons why, and explores some of strategies pharma can employ to unlock the potential of emerging markets.

Continue reading

Posted on 30/06/2017 | 0 Comments

Smart Hospitals: How technology is redefining future healthcare

Smart-hospitals

This next technological revolution – the technology redefining the healthcare industry of the future - is combining vast amounts of available data, cloud computing services, automation and machine learning, and creating artificial intelligence (AI)-based solutions that provide expert insight and analysis on a mass scale, at a relatively low cost. At the same time, connected sensors and medical devices are transforming the way the healthcare industry works. By 2020 the widespread adoption of technology-enabled care will ensure that the concept of the “Smart Hospital” becomes a reality. This week’s blog first appeared as an article that I wrote for Royal Philip linked to their launch of its Future Health Index.1 With their agreement I am repurposing the article as a Centre blog to share with our readers aimed at provoking discussion and debate.

Continue reading

Posted on 22/06/2017 | 0 Comments

Breaking the dependency cycle: Tackling health inequalities of vulnerable families

Dependency-cycle

 

All Western European countries have seen marked improvements in life expectancy over the past few decades, however, these countries also experience varying levels of in-country health inequalities. Indeed excess mortality and reductions in healthy life years are closely correlated to regional deprivation. Conventional explanations for health inequalities, such as lack of access to medical care and unhealthy lifestyles, provide only part of the explanation; the more intransigent causes include access to and opportunities in education, employment, housing, public transport and welfare services.

Continue reading

Posted on 16/06/2017 | 0 Comments

Caring with compassion: society’s most valuable resource?

Caring with compassion

Inspired by next week’s national Carers Week, an annual awareness campaign that celebrates the six and a half million people across the UK who provide unpaid care for a family member or friend, this week’s blog highlights the enormous challenges that carers face and recognises the vital contribution they make to families and communities throughout the UK.  Inspired by next week’s national Carers Week, an annual awareness campaign that celebrates the six and a half million people across the UK who provide unpaid care for a family member or friend, this week’s blog highlights the enormous challenges that carers face and recognises the vital contribution they make to families and communities throughout the UK.1

Continue reading

Posted on 09/06/2017 | 0 Comments

Predicting and preventing hospital readmission rates

Hospital

This week’s blog is written by our US colleague, Douglas Beaudoin, who is a Principal and leads Deloitte Consulting LLP’s Life Sciences and Health Care practice. This article first appeared in the US Center for Health Solutions blog, A View from the Center.1 The article highlights some of the work being done to lower readmissions and reduce unnecessary costs, which may also be pertinent to our system here in the UK.

Continue reading

Posted on 01/06/2017 | 1 Comments

Priorities for R&D leaders: innovation and collaboration

Priorities for R&D leaders.

This week marks the release of our first annual survey of pharmaceutical R&D leaders: Innovating to survive, collaborating to thrive. The report is written against a background of rapid changes in the way the pharmaceutical industry operates; with regulatory, health system and political environments all exerting unprecedented pressures on the returns that pharmaceutical companies are achieving from research and development (R&D). This week’s blog explores some of the key findings from the report.

Continue reading

Posted on 26/05/2017 | 1 Comments